Michael Cloonan - Sage Therapeutic Chief Business Officer
SAGE Stock | USD 12.89 0.44 3.30% |
Executive
Mr. Michael Cloonan is the Chief Business Officer of Sage Therapeutics, Inc. Mr. Cloonan has served as our Chief Business Officer since April 2017. Prior to joining us, Mr. Cloonan worked in various leadership positions at Biogen, Inc. from 2003 to 2017, including Senior Vice President, US Commercial from 2015 to 2017, Senior Vice President, Global Commercial Strategy from 2014 to 2015, Managing Director, Australia and New Zealand affiliate from 2011 to 2014, Vice President, Business Planning from 2010 to 2011, Senior Director, Patient Services US Commercial from 2008 to 2010, and Director, Business Planning from 2003 to 2008 since 2017.
Age | 47 |
Tenure | 7 years |
Professional Marks | MBA |
Address | 215 First Street, Cambridge, MA, United States, 02142 |
Phone | 617 299 8380 |
Web | https://www.sagerx.com |
Sage Therapeutic Management Efficiency
The company has return on total asset (ROA) of (0.3051) % which means that it has lost $0.3051 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5277) %, meaning that it created substantial loss on money invested by shareholders. Sage Therapeutic's management efficiency ratios could be used to measure how well Sage Therapeutic manages its routine affairs as well as how well it operates its assets and liabilities. As of April 23, 2024, Return On Tangible Assets is expected to decline to -0.64. In addition to that, Return On Capital Employed is expected to decline to -0.76. At present, Sage Therapeutic's Non Currrent Assets Other are projected to increase significantly based on the last few years of reporting. The current year's Other Assets is expected to grow to about 7.3 M, whereas Other Current Assets are forecasted to decline to about 20.8 M.Similar Executives
Showing other executives | EXECUTIVE Age | ||
Michael Morrissey | Incyte | 60 | |
Muthiah Manoharan | Alnylam Pharmaceuticals | 71 | |
Brian JD | Relay TherapeuticsInc | 50 | |
Kristin Hodous | Blueprint Medicines Corp | N/A | |
Paula Swain | Incyte | 66 | |
Christine Lindenboom | Alnylam Pharmaceuticals | 43 | |
John Grosso | Arvinas | 67 | |
David MD | Immunocore Holdings | 53 | |
Hubert MD | Krystal Biotech | 55 | |
Sheila MD | Ventyx Biosciences | 54 | |
Jennifer McDonough | Krystal Biotech | N/A | |
Susan MBA | Cerevel Therapeutics Holdings | 42 | |
Christine Wilson | Krystal Biotech | N/A | |
Christoph Lengauer | Blueprint Medicines Corp | 50 | |
Todd Verdoorn | DiaMedica Therapeutics | N/A | |
Jonathan JD | Stoke Therapeutics | 34 | |
Mike JD | Pliant TherapeuticsInc | 51 | |
Clint Wallace | Madrigal Pharmaceuticals | N/A | |
PharmD MBA | Incyte | 66 | |
JoAnn Suzich | Immunocore Holdings | N/A | |
Jared JD | Arvinas | 55 |
Management Performance
Return On Equity | -0.53 | ||||
Return On Asset | -0.31 |
Sage Therapeutic Leadership Team
Elected by the shareholders, the Sage Therapeutic's board of directors comprises two types of representatives: Sage Therapeutic inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sage. The board's role is to monitor Sage Therapeutic's management team and ensure that shareholders' interests are well served. Sage Therapeutic's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sage Therapeutic's outside directors are responsible for providing unbiased perspectives on the board's policies.
Howard Pien, Independent Director | ||
Christopher Benecchi, Chief Officer | ||
Laura MD, Chief Officer | ||
Kimi Iguchi, CFO | ||
Erin Lanciani, Vice President - Human Resources | ||
Anne Cook, Senior Vice President General Counsel, Secretary | ||
Kimi CPA, CFO Treasurer | ||
James Frates, Independent Director | ||
Frank Sanders, Vice President of Sales and Marketing | ||
Elizabeth Barrett, Director | ||
Matt Lasmanis, Chief Officer | ||
Jim Doherty, Chief Officer | ||
Geno Germano, Director | ||
Steven Paul, Independent Director | ||
Thomas Anderson, Chief Commercial Strategy Officer | ||
Albert Robichaud, Chief Scientific Officer | ||
Michael Cloonan, Chief Business Officer | ||
Anne Esq, General VP | ||
Robert Nelsen, Independent Director | ||
Ashley Kaplowitz, Director Relations | ||
Kevin Starr, Independent Director | ||
Amy Schacterle, Vice President - Regulatory Affairs and Quality Assurance | ||
Asha Nayak, Director | ||
Mike Quirk, Chief Officer | ||
George Golumbeski, Director | ||
Stephen Kanes, Chief Medical Officer | ||
Jeffrey Jonas, President CEO, Director | ||
Christopher Silber, Senior Vice President - Clinical Development | ||
Barry Greene, CEO President | ||
Paul Hodgkins, Vice President - Health Economics and Outcomes Research and Value Demonstration | ||
Helen Rubinstein, Investor Officer | ||
Michael Cola, Director |
Sage Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Sage Therapeutic a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -0.53 | ||||
Return On Asset | -0.31 | ||||
Operating Margin | (0.54) % | ||||
Current Valuation | 53.2 M | ||||
Shares Outstanding | 60.11 M | ||||
Shares Owned By Insiders | 12.56 % | ||||
Shares Owned By Institutions | 95.59 % | ||||
Number Of Shares Shorted | 8.6 M | ||||
Price To Earning | 3.07 X | ||||
Price To Book | 1.16 X |
Currently Active Assets on Macroaxis
When determining whether Sage Therapeutic is a strong investment it is important to analyze Sage Therapeutic's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Sage Therapeutic's future performance. For an informed investment choice regarding Sage Stock, refer to the following important reports:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sage Therapeutic. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. For information on how to trade Sage Stock refer to our How to Trade Sage Stock guide.Note that the Sage Therapeutic information on this page should be used as a complementary analysis to other Sage Therapeutic's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Complementary Tools for Sage Stock analysis
When running Sage Therapeutic's price analysis, check to measure Sage Therapeutic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sage Therapeutic is operating at the current time. Most of Sage Therapeutic's value examination focuses on studying past and present price action to predict the probability of Sage Therapeutic's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sage Therapeutic's price. Additionally, you may evaluate how the addition of Sage Therapeutic to your portfolios can decrease your overall portfolio volatility.
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity |
Is Sage Therapeutic's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sage Therapeutic. If investors know Sage will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sage Therapeutic listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (9.05) | Revenue Per Share 1.445 | Quarterly Revenue Growth 26.215 | Return On Assets (0.31) | Return On Equity (0.53) |
The market value of Sage Therapeutic is measured differently than its book value, which is the value of Sage that is recorded on the company's balance sheet. Investors also form their own opinion of Sage Therapeutic's value that differs from its market value or its book value, called intrinsic value, which is Sage Therapeutic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sage Therapeutic's market value can be influenced by many factors that don't directly affect Sage Therapeutic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sage Therapeutic's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sage Therapeutic is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sage Therapeutic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.